Enhertu Approved for HER2-Low Metastatic Breast Cancer
The approval was based on data from a phase 3 trial that included adults with unresectable or metastatic HER2-low breast cancer who had previous lines of chemotherapy.
Breast Cancer
July 2022 Recap: Drug Pipeline Updates
Stay up-to-date on the latest drugs in development.
Hormone Therapy Not Tied to Breast Cancer Recurrence, Mortality
No increased risk seen for women using either vaginal estrogen therapy or menopausal hormone therapy after diagnosis
Enhertu Gets Priority Review for HER2-Low Metastatic Breast Cancer
The sBLA is supported by data from the phase 3 DESTINY-Breast04 trials.
Pembrolizumab Ups Survival in Advanced Triple-Negative Breast Cancer
Overall survival longer with addition of pembrolizumab to chemo in tumors expressing PD-L1 with combined positive score of 10 or more
FDA to Review [Vic-]Trastuzumab Duocarmazine for HER2-Positive Metastatic Breast Cancer
The BLA is supported by data from the phase 3 TULIP trial which included 437 patients with HER2-positive unresectable locally advanced metastatic breast cancer.
Hormone Therapy-Related Hot Flashes Tied to Worse Breast Cancer Outcomes
Findings for chemotherapy-free patients with breast cancer
Metformin Does Not Improve Survival in High-Risk Breast Cancer
Incidence rate of invasive disease-free survival events and incidence rates for death did not differ with addition of metformin, placebo
April 2022: Drug Pipeline Updates
The table provided is a review of notable updates that occurred in April 2022 for investigational products in development.
